Avacta Group plc (AIM: AVCT), a clinical-stage life sciences company developing targeted oncology drugs, has announced new preclinical data for AVA6207, its next-generation dual payload peptide-drug conjugate, showing the candidate reversed topoisomerase 1 inhibitor resistance both in vitro and in animal models. The data were presented on 19 November 2026 at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The company confirmed that payloads have been selected and that AVA6207 moves into IND-enabling studies in Q4 2026, marking a significant progression milestone for the programme.

Key Points

  • Avacta Group plc (AIM: AVCT) — clinical-stage oncology drug developer headquartered in London and Philadelphia
  • AVA6207 reversed TOP1i resistance in vitro and in vivo using its proprietary pre|CISION® dual payload PDC technology
  • Complete responses observed in all animals with ovarian tumours and four of five animals with NSCLC tumours in PDX models; AVA6207 moves to IND-enabling studies in Q4 2026
  • Investors may be watching progress of IND-enabling studies and the company's strategy to identify biomarker-defined patient populations across CRC, NSCLC, ovarian cancer, and ESCC

AVA6207 Dual Payload Mechanism Targets SLFN11 Loss and ATM Loss to Reverse TOP1i Resistance

AVA6207 uses Avacta's pre|CISION® controlled-release technology to deliver two payloads — exatecan, a potent topoisomerase 1 inhibitor, and berzosertib, an ATR kinase inhibitor — directly to tumour cells via a single FAP cleavage event. The announcement states that in SLFN11-deficient cells, AVA6207 forced resistant cells into fatal mitotic catastrophe. In ATM-deficient cells, the compound demonstrated approximately tenfold higher sensitivity compared with ATM-positive cells, with assays confirming the compound can induce synthetic lethality. Both mechanisms leave tumours dependent on ATR kinase for survival, the precise vulnerability AVA6207 is designed to exploit.

AVA6207 Achieves Complete Responses in Ovarian and NSCLC Patient-Derived Xenograft Models

In vivo patient-derived xenograft models demonstrated robust activity in ATM-low and SLFN11-low non-small cell lung cancer and ATM-positive, SLFN11-low ovarian cancer settings. The announcement states AVA6207 achieved complete responses in all animals with ovarian tumours and in four of five animals with NSCLC tumours. The candidate also demonstrated superiority to the marketed antibody-drug conjugate Enhertu® in a gastric PDX model. The company notes that the addressable markets across the US, EU5, and Japan range from approximately 150,000–250,000 annual incidences in NSCLC to 4,000–20,000 in the rarer ESCC orphan subsets.

AVA6207 Advances to IND-Enabling Studies as Avacta Pursues Biomarker-Defined Clinical Strategy

With payloads confirmed, Avacta has moved AVA6207 into IND-enabling studies in Q4 2026. The company is evaluating clinical indications including colorectal cancer, NSCLC, ovarian cancer, and oesophageal squamous cell cancer, targeting biomarker-defined populations with SLFN11 loss or ATM deficiency. The announcement notes that this enrichment strategy is designed to identify patient groups most likely to benefit. The disclosure also highlights consistency across Avacta's pre|CISION® pipeline, referencing AVA6103 and AVA6000 alongside AVA6207, as the company seeks to generate capital investment to advance multiple programmes towards clinical development.